“…There is also in vitro evidence that CBDA activates the transient receptor potential (TRP) cation channels, TRPV1 (EC50 = 19.7 Ϯ 3.9 mM) and TRPA1 (EC50 = 12.0 Ϯ 8.8 mM), and antagonizes TRPM8 (IC50 = 1.6 Ϯ 0.4 mM) (De Petrocellis et al, 2008;De Petrocellis et al, 2011). Furthermore, CBDA has been found to affect the contractility of gastrointestinal tissue of S. murinus in vitro, as indicated by its ability, at 10 mM, to reduce both the magnitude of contractions induced by carbachol or by electrical field stimulation and the tension of intestinal segments that had been pre-contracted with potassium chloride (Cluny et al, 2011). In addition, Takeda et al (2008) have reported that CBDA (IC50 = 2 mM) is a selective inhibitor of COX-2, an enzyme expressed by cells undergoing inflammation; however, Ruhaak et al (2011) found more recently that CBDA did not inhibit this enzyme, but rather COX-1 (IC50 = 4.7 ¥ 10 -4 M), prompting a need for further research.…”